NCT01756352View on ClinicalTrials.gov

FET-PET for Evaluation of Response of Recurrent GBM to Avastin

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

September 13, 2015

Study Completion Date

September 13, 2015

Conditions
Glioblastoma MultiformeGBM
Interventions
DRUG

18F-FET

Radiotracer, surrogate marker for protein synthesis

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Marcelo F. Di Carli, MD, FACC

OTHER

NCT01756352 - FET-PET for Evaluation of Response of Recurrent GBM to Avastin | Biotech Hunter | Biotech Hunter